Development of Nanoparticles for Drug Delivery to Brain Tumor: The Effect of Surface Materials on Penetration Into Brain Tissue

Steeg, 2016, Targeting metastasis, Nat Rev Cancer, 16, 201, 10.1038/nrc.2016.25 Davoodi, 2017, Effective co-delivery of nutlin-3a and p53 genes via core–shell microparticles for disruption of MDM2–p53 interaction and reactivation of p53 in hepatocellular carcinoma, J Mater Chem B, 5, 5816, 10.1039/C7TB00481H Biemar, 2013, Global progress against cancer-challenges and opportunities, Cancer Biol Med, 10, 183 Davoodi, 2016, Double-walled microparticles-embedded self-cross-linked, injectable, and antibacterial hydrogel for controlled and sustained release of chemotherapeutic agents, ACS Appl Mater Interfaces, 8, 22785, 10.1021/acsami.6b03041 Davoodi, 2018, Drug delivery systems for programmed and on-demand release, Adv Drug Deliv Rev, 132, 104, 10.1016/j.addr.2018.07.002 Raavé, 2018, Chemotherapeutic drug delivery by tumoral extracellular matrix targeting, J Control Release, 274, 1, 10.1016/j.jconrel.2018.01.029 Chen, 2016, Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance, Nanomedicine, 12, 269, 10.1016/j.nano.2015.10.020 Graff, 2005, Nasal drug administration: potential for targeted central nervous system delivery, J Pharm Sci, 94, 1187, 10.1002/jps.20318 Oberoi, 2016, Strategies to improve delivery of anticancer drugs across the blood–brain barrier to treat glioblastoma, Neuro Oncol, 18, 27, 10.1093/neuonc/nov164 van Tellingen, 2015, Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy, Drug Resist Updat, 19, 1, 10.1016/j.drup.2015.02.002 Naik, 2012, In vitro blood–brain barrier models: current and perspective technologies, J Pharm Sci, 101, 1337, 10.1002/jps.23022 Saenz del Burgo, 2014, Nanotherapeutic approaches for brain cancer management, Nanomedicine, 10, e905, 10.1016/j.nano.2013.10.001 Mäger, 2017, Targeting blood-brain-barrier transcytosis - perspectives for drug delivery, Neuropharmacology, 120, 4, 10.1016/j.neuropharm.2016.08.025 Pardridge, 2003, Blood-brain barrier drug targeting: the future of brain drug development, Mol Interv, 3, 90, 10.1124/mi.3.2.90 Abbott, 2010, Structure and function of the blood-brain barrier, Neurobiol Dis, 37, 13, 10.1016/j.nbd.2009.07.030 Wijaya, 2017, Obstacles to brain tumor therapy: key ABC transporters, Int J Mol Sci, 18, 2544, 10.3390/ijms18122544 Henson, 1992, P-glycoprotein expression in brain tumors, J Neuro Oncol, 14, 37 Cole, 1998, Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP, Bioessays, 20, 931, 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J Wu, 2014, The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy, Acta Pharm Sin B, 4, 105, 10.1016/j.apsb.2013.12.001 Cahan, 1994, Cytotoxicity of taxol in vitro against human and rat malignant brain tumors, Cancer Chemother Pharmacol, 33, 441, 10.1007/BF00686276 Hempel, 2003, Population pharmacokinetics of low-dose paclitaxel in patients with brain tumors, Anticancer Drugs, 14, 417, 10.1097/00001813-200307000-00005 Zhao, 2010, Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies, J Pharm Sci, 99, 3552, 10.1002/jps.22113 Gelderblom, 2001, The drawbacks and advantages of vehicle selection for drug formulation, Eur J Cancer, 37, 1590, 10.1016/S0959-8049(01)00171-X Jones, 2007, Blood-brain barrier transport of therapeutics via receptor-mediation, Pharm Res, 24, 1759, 10.1007/s11095-007-9379-0 Grabrucker, 2016, Nanoparticle transport across the blood brain barrier, Tissue Barriers, 4, e1153568, 10.1080/21688370.2016.1153568 Gao, 2014, Nanotechnology-based intelligent drug design for cancer metastasis treatment, Biotechnol Adv, 32, 761, 10.1016/j.biotechadv.2013.10.013 Shen, 2016, Decorating nanoparticle surface for targeted drug delivery: opportunities and challenges, Polymers, 8, 83, 10.3390/polym8030083 Lakkadwala, 2018, Dual functionalized 5-fluorouracil liposomes as highly efficient nanomedicine for glioblastoma treatment as assessed in an in vitro brain tumor model, J Pharm Sci, 107, 2902, 10.1016/j.xphs.2018.07.020 Liu, 2014, In vitro and in vivo studies on the transport of PEGylated silica nanoparticles across the blood-brain barrier, ACS Appl Mater Interfaces, 6, 2131, 10.1021/am405219u Saraiva, 2016, Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases, J Control Release, 235, 34, 10.1016/j.jconrel.2016.05.044 Betzer, 2017, The effect of nanoparticle size on the ability to cross the blood-brain barrier: an in vivo study, Nanomedicine, 12, 1533, 10.2217/nnm-2017-0022 Simpson, 2013, In vivo toxicity, biodistribution, and clearance of glutathione-coated gold nanoparticles, Nanomedicine, 9, 257, 10.1016/j.nano.2012.06.002 Jo, 2015, Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases, Nanomedicine, 11, 1603, 10.1016/j.nano.2015.04.015 Hu, 2018, The characterization, pharmacokinetic, and tissue distribution studies of TPGS-modified artesunate liposome in rats, Drug Dev Ind Pharm, 44, 1528, 10.1080/03639045.2018.1483383 Yang, 2018, Recent advances in the application of vitamin E TPGS for drug delivery, Theranostics, 8, 464, 10.7150/thno.22711 Fonseca, 2002, Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity, J Control Release, 83, 273, 10.1016/S0168-3659(02)00212-2 Dong, 2004, Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs, Biomaterials, 25, 2843, 10.1016/j.biomaterials.2003.09.055 Chorny, 2002, Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics, J Control Release, 83, 389, 10.1016/S0168-3659(02)00211-0 Faraji, 2009, Nanoparticles in cellular drug delivery, Bioorg Med Chem, 17, 2950, 10.1016/j.bmc.2009.02.043 Zauner, 2001, In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density, J Control Release, 71, 39, 10.1016/S0168-3659(00)00358-8 Yin Win, 2005, Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs, Biomaterials, 26, 2713, 10.1016/j.biomaterials.2004.07.050 Davis, 2008, Nanoparticle therapeutics: an emerging treatment modality for cancer, Nat Rev Drug Discov, 7, 771, 10.1038/nrd2614 Zhang, 2008, In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy, Pharm Res, 25, 1925, 10.1007/s11095-008-9611-6 Dintaman, 1999, Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS), Pharm Res, 16, 1550, 10.1023/A:1015000503629 Lopes, 1993, Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines, Cancer Chemother Pharmacol, 32, 235, 10.1007/BF00685842 Liebmann, 1994, The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines, Cancer Chemother Pharmacol, 33, 331, 10.1007/BF00685909 Liebmann, 1993, Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines, Br J Cancer, 68, 1104, 10.1038/bjc.1993.488 Hu, 2009, Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations, J Control Release, 134, 55, 10.1016/j.jconrel.2008.10.016 Rabinovitch, 1995, Professional and non-professional phagocytes: an introduction, Trends Cell Biol, 5, 85, 10.1016/S0962-8924(00)88955-2 Gao, 2005, Mechanics of receptor-mediated endocytosis, Proc Natl Acad Sci U S A, 102, 9469, 10.1073/pnas.0503879102 He, 2010, Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles, Biomaterials, 31, 3657, 10.1016/j.biomaterials.2010.01.065 Mu, 2003, A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS, J Control Release, 86, 33, 10.1016/S0168-3659(02)00320-6 Petri, 2007, Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants, J Control Release, 117, 51, 10.1016/j.jconrel.2006.10.015 Herrera, 2001, Vitamin E: action, metabolism and perspectives, J Physiol Biochem, 57, 43, 10.1007/BF03179812 Jung, 2000, Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?, Eur J Pharm Biopharm, 50, 147, 10.1016/S0939-6411(00)00084-9 Regev, 1999, Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells, Eur J Biochem, 259, 18, 10.1046/j.1432-1327.1999.00037.x Tang, 2013, Vitamin E reverses multidrug resistance in vitro and in vivo, Cancer Lett, 336, 149, 10.1016/j.canlet.2013.04.020 Kulkarni, 2011, Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood-brain barrier, Nanomedicine (Lond), 6, 377, 10.2217/nnm.10.131 Gulyaev, 1999, Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles, Pharm Res, 16, 1564, 10.1023/A:1018983904537 Steiniger, 1999, The influence of polysorbate 80-coated nanoparticles on bovine brain capillary endothelial cells in vitro, Proc Int Symp Control Rel Bioact Mater, 26, 789 Wilson, 2009, Brain targeting PBCA nanoparticles and the blood-brain barrier, Nanomedicine (Lond), 4, 499, 10.2217/nnm.09.29 Muthu, 2012, Development of docetaxel-loaded vitamin E TPGS micelles: formulation optimization, effects on brain cancer cells and biodistribution in rats, Nanomedicine (Lond), 7, 353, 10.2217/nnm.11.111